Abbott Laboratories is poised to benefit from a resurgence in its adult nutrition business during Q4. The recent launches of Ensure Max Protein and an expanded lineup of Glucerna diabetes-management shakes are projected to drive 4% organic growth in the segment over the previous quarter. Management highlighted that Ensure’s new formulation has already secured distribution in more than 25,000 pharmacies across North America, representing a 15% increase in outlet counts, and Glucerna innovations have generated order volumes up 12% year-over-year in early December.

In Q3 2025, Abbott delivered normalized EPS of $1.30, flat with consensus estimates, alongside revenues of $9.8 billion, up 6.8% year-over-year but trailing consensus by $20 million. International markets were the strongest contributors, with revenue growth of 9.2% in Europe and 11.5% in Asia Pacific, offsetting a 2% decline in U.S. electrophysiology sales. For Q4, analysts forecast mid-single-digit revenue growth overall, driven primarily by 3–5% growth in diagnostics and the aforementioned adult nutrition uptick, with normalized EPS guidance ranging from $1.32 to $1.35.

Abbott’s ongoing cost-saving initiatives are expected to bolster margins in Q4. The company achieved $180 million in run-rate savings from its Global Efficiency Program by the end of Q3, exceeding the $150 million target. These efficiencies stem largely from optimized supply-chain operations and consolidated manufacturing shifts in Puerto Rico and Ireland. As a result, adjusted operating margins in Q4 are projected to expand by approximately 50 basis points compared with last year’s quarter.

Abbott’s relative flat performance over the past 15 months, underperforming the S&P 500’s 17.5% total return, has weighed on sentiment. However, the combination of robust adult nutrition sales, steady diagnostics demand, and disciplined cost controls may mark a turning point. Institutional investors are watching Q4 results closely to assess whether Abbott can reaccelerate top-line growth above 5% in 2026 and restore earnings-per-share growth to a mid-teens percentage range.